Elanco Animal Health Incorporated (NYSE:ELAN) Short Interest Update

Elanco Animal Health Incorporated (NYSE:ELAN) was the target of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 15,072,733 shares, a decrease of 18.1% from the February 12th total of 18,414,142 shares. Currently, 3.1% of the shares of the stock are short sold. Based on an average daily volume of 5,231,386 shares, the short-interest ratio is presently 2.9 days. Based on an average daily volume of 5,231,386 shares, the short-interest ratio is presently 2.9 days. Currently, 3.1% of the shares of the stock are short sold.

Institutional Trading of Elanco Animal Health

Hedge funds have recently added to or reduced their stakes in the business. Parallel Advisors LLC boosted its stake in Elanco Animal Health by 5.9% during the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock valued at $160,000 after purchasing an additional 392 shares during the last quarter. Lazard Asset Management LLC boosted its position in shares of Elanco Animal Health by 0.6% during the fourth quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares during the last quarter. Northwestern Mutual Investment Management Company LLC raised its holdings in shares of Elanco Animal Health by 0.4% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after acquiring an additional 428 shares in the last quarter. Meeder Advisory Services Inc. grew its stake in shares of Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after buying an additional 510 shares in the last quarter. Finally, Root Financial Partners LLC raised its position in shares of Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Stock Down 1.1%

NYSE:ELAN opened at $24.90 on Wednesday. The company has a market cap of $12.38 billion, a PE ratio of -51.94, a PEG ratio of 2.98 and a beta of 1.83. Elanco Animal Health has a 52-week low of $8.02 and a 52-week high of $27.72. The stock has a 50-day simple moving average of $24.56 and a 200 day simple moving average of $22.33. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. On average, sell-side analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Morgan Stanley upped their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Wednesday, November 19th. Finally, KeyCorp boosted their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.